Read More

Netflix’s Advertising Strategy Promises Big, with 40M Ad-Supported Viewers and Unique Ad Integration Plans, Analysts Says After Event

Oppenheimer analyst reiterated Outperform rating on Netflix with price target of $725. Netflix showcased robust content slate, ad partnerships, & upcoming ad platform launch. Ad revenue ramp may take time. Other analysts maintained Neutral/Sell ratings.

GOOGL

Read More

Analysts Remain Bullish on Take-Two Interactive Despite GTA VI Delay, Anticipate Strong Long-Term Growth

Take-Two Interactive Software posted strong FY4Q results, with a FY2025 net bookings outlook of $5.55-$5.65 billion. Stifel's Drew Crum noted the anticipation around GTA VI's fall 2025 launch, despite some frustration from investors. Analysts from Stifel, Benchmark, and Roth MKM reiterated their Buy ratings, with price targets ranging from $175 to $200, citing optimism for long-term growth.

TTWO

Read More

AbbVie Is ‘Successfully Positioned To Absorb Humira Biosimilar Erosion’: Analyst

Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine, and achieve a high single-digit CAGR from 2024 to 2029.

ABBV